Company News
-
FDA approves ibrutinib for the treatment of chronic graft-versus-host disease ( cGVHD ) in children
On August 24, 2022, the U.S. Food and Drug Administration (FDA) approved ibrutinib for the treatment of pediatric patients older than 1 year with chronic graft-versus-host disease ( cGVHD ) who are receiving After failure of 1- or multi-line systemic therapy . The approved indication is mainly fo...Read more -
Big News! SyncoZymes (Shanghai) Co., Ltd. The world’s first NMN raw material passed FDA NDI certification.
After strict review by the professional committee of the US FDA (US Food and Drug Administration) authoritative organization, on May 17, 2022, SyncoZymes (Shanghai) Co., Ltd. officially received the FDA's confirmation letter (AKL): NMN raw material successfully passed ND...Read more -
Zhejiang Syncozymes Biopharmaceutical Co., Ltd. The enzyme catalysis project passed the preliminary review of the key research and development plan of Zhejiang Province
In August 2020, the “Bio-enzyme Library Development and Green Catalytic Synthesis Application” project of Zhejiang Shangke Biopharmaceutical Co., Ltd. passed the preliminary review of the Zhejiang Provincial Key R&D Program of the Zhejiang Provincial Department of Science and Tech...Read more -
Big news: Syncozymes has an annual output of 100 tons of coenzyme NMN/NADH/NAD series. These ingredients will be put into production
Syncozymes's annual production of 100 tons of coenzyme NMN/NADH/NAD series products will be officially put into production in October this year! (Zhejiang Syncozymes Bio-pharmaceutical Co., Ltd.) As the foreru...Read more -
Good news: Syncozymes has been recognized as a high-tech achievement transformation project
On January 5, 2021, Shangke Biopharmaceutical (Shanghai) Co., Ltd. was awarded the "(S)-1-tert-butoxycarbonyl-3-hydroxypiperidine" Shanghai High-tech Achievement Transformation Project. As a national high-tech enterprise, Suntech Biotech always takes biotechnology to lea...Read more -
[During the Expo]: Syncozymes won the title of the first batch of enterprises to settle in the “Global Matchmaking Club”
The "Global Matchmaking Club" cross-border matchmaking platform is independently developed by ICBC and is open to global enterprises free of charge. Matching activities and other core functions. Since the platform was launched for more than two months, it has attracted n...Read more -
Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition and made a special academic report on NMN
On October 14, 2020, the 85th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (referred to as API China API) opened at the Nanjing International Expo Center. Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nan...Read more -
[Good news] Syncozymes’s NMN products have passed the safety certification of SELF GRAS in the United States
In September 2020, Syncozymes’s NMN products passed the SELF GRAS (US Safety Index for Evaluation of Food Additives) safety certification. NMN has been dubbed the “elixir” by the public, and its main function is to repair DNA, healthy cells, and relieve various diseases caused ...Read more -
Syncozymes’s NMN raw material passed the “Acute Oral Toxicity Test”
The recent outbreak of the concept of “longevity medicine” NMN has caused shocks in the capital market. In mid-July, the “Internet celebrity longevity medicine” NMN concept stock became a dark horse in the market. The stocks of related companies have been closed one after ...Read more